HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
Read original at benzingaStocks · News reference
OmniAb shares are trading higher after the company revised its FY26 Cash and Cash Equivalent guidance above prior expectations. The company announced a a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:49 PM
- Checked
- Aug 17, 2026, 12:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
Read original at benzingaH World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.
Read original at benzingaWhy Is Omniab Stock Rallying After Eli Lilly Deal?
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Read original at benzinga